GLP-1 Receptor Agonist Market, by Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Albiglutide, and Semaglutide), by Route of Administration (Parenteral and Oral), by Application (Type 2 Diabetes Mellitus, Obesity, Liver Cirrhosis, Non-alcoh

GLP-1 Receptor Agonist Market, by Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Albiglutide, and Semaglutide), by Route of Administration (Parenteral and Oral), by Application (Type 2 Diabetes Mellitus, Obesity, Liver Cirrhosis, Non-alcoholic Steatohepatitis, and Others {Others include Cardiovascular Disease and Type-1 Diabetes}), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

GLP-1 receptor (Glucagon like peptide-1 receptor) is a receptor protein found in the neurons of the brain and the beta cells of pancreas. GLP-1 receptor is involved in regulating the process of insulin secretion in the body. GLP-1 and glucagon are the natural endogenous agonists of GLP-1 receptor. An agonist is a chemical entity which induces a biological response by binding to a receptor and activating it. Some of the other agonists of GLP-1 receptor include exenatide, lixisenatide, albiglutide, liraglutide, dulaglutide, and semaglutide. GLP-1 receptor agonists are commonly used for the treatment of diabetes and obesity. When an agonist binds to the GLP-1 receptor the receptor becomes activated and results in stimulation of adenylyl cyclase pathway. Adenylyl cyclase pathway leads to increased production and release of insulin in the beta cells of pancreas. GLP-1 receptors expressed in the brain neurons are responsible for controlling appetite. GLP-1 receptor is also expressed in stretch responsive sensory neurons of the stomach and intestines. These GLP-1 receptor neurons, when activated can cause changes in the breathing and heart rate. GLP-1 receptor agonists, also known as incretin mimetics, are advantageous over traditional insulin secretagogues, such as sulfonylureas or meglitinides as they pose a low risk of causing hypoglycemia or low blood sugar.
Market Dynamics
The increasing incidence of diabetes and obesity, rising research and development activities for the development of novel therapeutics for the treatment of diabetes and obesity, and increasing adoption of inorganic growth strategies such as merger, acquisitions, distributive agreements, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global GLP-1 receptor agonist market over the forecast period.
For instance, according to the Pan American Journal of Public Health, the number of people living with type 1 diabetes in the Americas is expected to increase from 35 million in 2000 to 64 million in 2025, out of which Latin America and Caribbean region would account for 62% or 40 million people in 2025.
Key features of the study:
This report provides in-depth analysis of the global GLP-1 receptor agonist market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global GLP-1 receptor agonist market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Eli Lilly and Company, GlaxoSmithKline plc, Novo Nordisk A/S, PegBio Co., Ltd., AstraZeneca, Intarcia Therapeutics, Inc., Amylin Pharmaceuticals, Inc., Sanofi, Hanmi Pharm. Co., Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics, Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., and 9 Meters Biopharma, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global GLP-1 receptor agonist market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global GLP-1 receptor agonist market
Detailed Segmentation:
Global GLP-1 Receptor Agonist Market, By Drug Class:
Exenatide
Liraglutide
Dulaglutide
Lixisenatide
Albiglutide
Semaglutide
Global GLP-1 Receptor Agonist Market, By Route of Administration:
Parenteral
Oral
Global GLP-1 Receptor Agonist Market, By Application:
Type 2 Diabetes Mellitus
Obesity
Liver Cirrhosis
Non-alcoholic Steatohepatitis
Others (Others include Cardiovascular Disease and Type-1 Diabetes)
Global GLP-1 Receptor Agonist Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global GLP-1 Receptor Agonist Market, By Region:
North America
By Drug Class
Exenatide
Liraglutide
Dulaglutide
Lixisenatide
Albiglutide
Semaglutide
By Route of Administration
Parenteral
Oral
By Application
Type 2 Diabetes Mellitus
Obesity
Liver Cirrhosis
Non-alcoholic Steatohepatitis
Others (Others include Cardiovascular Disease and Type-1 Diabetes)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Drug Class
Exenatide
Liraglutide
Dulaglutide
Lixisenatide
Albiglutide
Semaglutide
By Route of Administration
Parenteral
Oral
By Application
Type 2 Diabetes Mellitus
Obesity
Liver Cirrhosis
Non-alcoholic Steatohepatitis
Others (Others include Cardiovascular Disease and Type-1 Diabetes)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class
Exenatide
Liraglutide
Dulaglutide
Lixisenatide
Albiglutide
Semaglutide
By Route of Administration
Parenteral
Oral
By Application
Type 2 Diabetes Mellitus
Obesity
Liver Cirrhosis
Non-alcoholic Steatohepatitis
Others (Others include Cardiovascular Disease and Type-1 Diabetes)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class
Exenatide
Liraglutide
Dulaglutide
Lixisenatide
Albiglutide
Semaglutide
By Route of Administration
Parenteral
Oral
By Application
Type 2 Diabetes Mellitus
Obesity
Liver Cirrhosis
Non-alcoholic Steatohepatitis
Others (Others include Cardiovascular Disease and Type-1 Diabetes)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class
Exenatide
Liraglutide
Dulaglutide
Lixisenatide
Albiglutide
Semaglutide
By Route of Administration
Parenteral
Oral
By Application
Type 2 Diabetes Mellitus
Obesity
Liver Cirrhosis
Non-alcoholic Steatohepatitis
Others (Others include Cardiovascular Disease and Type-1 Diabetes)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Drug Class
Exenatide
Liraglutide
Dulaglutide
Lixisenatide
Albiglutide
Semaglutide
By Route of Administration
Parenteral
Oral
By Application
Type 2 Diabetes Mellitus
Obesity
Liver Cirrhosis
Non-alcoholic Steatohepatitis
Others (Others include Cardiovascular Disease and Type-1 Diabetes)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Eli Lilly and Company*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
GlaxoSmithKline plc
Novo Nordisk A/S
PegBio Co., Ltd.
AstraZeneca
Intarcia Therapeutics, Inc.
Amylin Pharmaceuticals, Inc.
Sanofi
Hanmi Pharm. Co., Ltd.
Pfizer Inc.
Amgen Inc.
Innovent Biologics
Jiangsu Hengrui Medicine Co.
Sun Pharmaceuticals Industries Ltd.
9 Meters Biopharma, Inc.
“*” marked represents similar segmentation in other categories in the respective section.